• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study]

byDevin MillerandXiaozhou Liu
July 15, 2014
in Chronic Disease, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Survival improved for most types of hematologic malignancies in Europe between 1992 and 2007. 

2. The improvements in survival for various malignancies were not geographically uniform throughout the European continent. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Recent advancements in the treatment of hematologic malignancies, including the introduction of drugs such as rituximab, imatinib, and bortezomib, have changed the survival outlook for many patients. Prior to this study, there had been no large scale examinations of survival trends in patients with hematologic malignancies in Europe. The authors of this study set out to describe the 5-year survival for each different type of malignancy in addition to estimating the relative excess risk of death 5 years following diagnosis stratified by age, time period, and continental region. The study found an overall improvement in survival throughout the European continent. The improvements were not geographically uniform. This study benefited from the fact that patient data were drawn from large cancer registries, representing geographic regions as a whole rather than information gathered from individual centers of excellence. A drawback to this study is that little to no information was collected regarding confounding variables such as treatment type, stage of diagnosis, or comorbidities.

Click to read the study, published today in The Lancet Oncology

Relevant Reading: Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 a population-based study

RELATED REPORTS

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma

In-Depth [retrospective cohort]: This study included 560,444 individuals greater than 15 years of age with hematologic malignancies from the EUROCARE-5 database between 1996 and 2007. Non-Hodgkin lymphoma was the most common malignancy (40.1%) followed next by myeloid malignancies (24.9%), multiple myeloma/plasmacytoma (15.0%), not otherwise specified (13.7%), and Hodgkin’s lymphoma (6.3%).

5-year survival increased significantly over the study period for all lymphoid malignancies with follicular lymphoma and large B-cell lymphoma having the largest increases, (58.9% [95% confidence interval, CI, 57.3-60.6] in 1997-99 to 74.3% [95% CI, 72.9-75.5] in 2006-08 and 29.8% [95% CI, 27.7-32.0] in 1997-99 to 41.1% (95% CI, 39.0-43.1) in 2006-08, respectively, p < 0.0001). Younger patients tended to have better 5-year survival than older patients as well as having a greater increase in survival over the study period.

More from this author: Vitamin D may reduce the risk of hypertension,Schizophrenia linked with higher rates of violence, suicide, and early mortality;Overall improvement in management of high blood pressure between 1994 and 2011;Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity;Structural and neurobiological foundations of suicide, a review;Buccal administration of dextrose gel effective in treatment of neonatal hypoglycemia 

Image: PD 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: bortezomibhodgkin'simatiniblymphomarituximab
Previous Post

Social integration may reduce suicide risk in male health professionals

Next Post

Recurrent pregnancy loss associated with increased cardiovascular morbidity

RelatedReports

Chemotherapy and stem-cell transplant for multiple myeloma remain superior
Hematology

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

March 7, 2025
#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk
StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024
Adaptive interim PET-CT guides treatment for advanced Hodgkin’s lymphoma
Chronic Disease

Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma

November 21, 2024
Nivolumab+AVD Improves Survival in  Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD
StudyGraphics

Nivolumab+AVD Improves Survival in Advanced Classic Hodgkin’s Lymphoma Compared to Brentuximab Vedotin+AVD

October 30, 2024
Next Post
Soaring rates of peripheral artery disease, now over 200 million cases worldwide

Recurrent pregnancy loss associated with increased cardiovascular morbidity

Higher omega-3 blood levels associated with larger brain volumes

Diets rich in omega fatty acids may reduce ALS (Lou Gehrig's) risk

No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]

No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.